Open AccessEffects of moxonidine and combination of moxonidine and ivabradine on insulin resistance in patients with metabolic syndrome
Author(s) -
M.N. Azimova,
Азимова Медина Нуреддиновна,
А Б Бахшалиев,
Бахшалиев Адиль Бахшалиевич,
С М Кахраманова,
Кахраманова Сонна Маисовна,
Gulnaz Dadashova,
Дадашова Гюльназ Махировна
Publication year - 2015
Publication title -
kazanskij medicinskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2587-9359
pISSN - 0368-4814
DOI - 10.17750/kmj2015-032
Subject(s) - moxonidine , metabolic syndrome , insulin resistance , glycated hemoglobin , medicine , endocrinology , insulin , obesity , overweight , body mass index , homeostatic model assessment , diabetes mellitus , type 2 diabetes , agonist , receptor
Aim. To explore the features of insulin resistance variations in overweight and obese patients with metabolic syndrome treated with moxonidine and combination of moxonidine and ivabradine.Methods. The study included 30 patients with metabolic syndrome, who were overweight (body mass index 26.9±0.2 kg/m2) and 30 patients with metabolic syndrome and obesity (BMI 34.2±0.3). Control group included 17 healthy volunteers matched with patients by age and sex. Patients with metabolic syndrome and excessive body weight received moxonidine twice daily in average daily dose of 0.58±0.07 mg. Patients with metabolic syndrome and obesity received moxonidine twice daily in average daily dose of 0.52±0.04 mg and ivabradine twice daily in average daily dose of 13.7±1.1 mg. Biochemical blood tests (insulin, C-peptide, glucose, glycated hemoglobin serum levels) were performed in all patients.Results.Patients with metabolic syndrome and obesity tended to increase insulin resistance, compared to individuals with metabolic syndrome and excessive body weight. In overweight patients with metabolic syndrome treated with moxonidine, a trend for lower insulin resistance, accompanied by a decrease of insulin, C-peptide, glycosylated hemoglobin, glucose levels and homeostasis model assessment-estimated insulin resistance (HOMA-IR) index by 7.1, 2.0, 5.0, 7.3 and 12.2% respectively was discovered. Combination therapy with moxonidine and ivabradine in patients with metabolic syndrome and obesity leaded to a statistically significant improvement of insulin resistance, accompanied by a decrease of insulin levels, glucose, C-peptide, and glycated hemoglobin by 16.7%, 12.3% (pConclusion. In patients with metabolic syndrome, deepening of insulin resistance on the background of increased sympathetic activity is associated with higher grades of obesity. Combination therapy with moxonidine and ivabradine in patients with metabolic syndrome and obesity leads to a significant improvement in insulin resistance due to the additional sympatholytic effect.